Exact Mass: 397.2127214
Exact Mass Matches: 397.2127214
Found 500 metabolites which its exact mass value is equals to given mass value 397.2127214,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Echimidine
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2304 INTERNAL_ID 2304; CONFIDENCE Reference Standard (Level 1)
Apatinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
Phytosphingosine-1-P
C18H40NO6P (397.2593110000001)
Phytosphingosine-1-P is an intermediate in sphingolipid metabolism pathway. It is the enzymatic oxidation product of 4-hydroxysphinganine. Sphingolipids are essential components of the plasma membrane in all eukaryotic cells. S. cerevisiae cells make three complex sphingolipids: inositol-phosphoceramide (IPC), mannose-inositol-phosphoceramide (MIPC), and mannosyl-diinositol-phosphorylceramide (M(IP)2C) [ Dickson02 ]. In the yeast plasma membrane sphingolipids concentrate with ergosterol to form lipid rafts, specialized membrane microdomains implicated in a variety of cellular processes, including sorting of membrane proteins and lipids, as well as organizing and regulating signaling cascades [ Bagnat02 ]. Intermediates in sphingolipid biosynthesis have been shown to play important roles as signaling molecules and growth regulators. Sphingolipid long chain bases (LCBs), dihydrosphingosine (DHS) and phytosphingosine (PHS), have been implicated as secondary messengers in signaling pathways that regulate heat stress response. Other intermediates, phytoceramide and long-chain base phosphates (LCBPs), have been shown to be components of tightly-controlled ceramide/LCBP rheostat, which regulates cell growth. Since phosphoinositol-containing sphingolipids are unique to fungi, the sphingolipid biosynthesis pathway is considered a target for antifungal drugs. Phytosphingosine-1-p, also known as phs-1-phosphate, is a member of the class of compounds known as phosphosphingolipids. Phosphosphingolipids are sphingolipids with a structure based on a sphingoid base that is attached to a phosphate head group. They differ from phosphonospingolipids which have a phosphonate head group. Phytosphingosine-1-p is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Phytosphingosine-1-p can be found in a number of food items such as dandelion, common verbena, turmeric, and fennel, which makes phytosphingosine-1-p a potential biomarker for the consumption of these food products.
Drotaverine
C24H31NO4 (397.22529660000004)
Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been shown to possess dose-dependant analgesic effects in animal models. One small study has shown drotaverine to be eliminated mainly non-renally. A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AD - Papaverine and derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Tetradeca-9,11-dienedioylcarnitine
C21H35NO6 (397.24642500000004)
Tetradeca-9,11-dienedioylcarnitine is an acylcarnitine. More specifically, it is an tetradeca-9,11-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tetradeca-9,11-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tetradeca-9,11-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6E,9E)-Tetradeca-6,9-dienedioylcarnitine
C21H35NO6 (397.24642500000004)
(6E,9E)-Tetradeca-6,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E)-tetradeca-6,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E)-Tetradeca-6,9-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E)-Tetradeca-6,9-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine
C21H35NO6 (397.24642500000004)
(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z)-tetradeca-2,4-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4Z)-Tetradeca-2,4-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E,4Z)-Tetradeca-2,4-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
1-(3,4-Diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline
C24H31NO4 (397.22529660000004)
4-Tetradecanamidobenzylphosphonic acid
C21H36NO4P (397.2381826000001)
Navarixin
C21H23N3O5 (397.16376280000003)
Comfrey
Apatinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine
Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate
2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one
C22H19N7O (397.16510040000003)
6-[[3-Fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]-1-methylquinolin-2-one
Abexinostat
C21H23N3O5 (397.16376280000003)
D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
Reduced ketanserin
N-Acetyl-9-aminominocycline, (4R)-
Vilmorrianone
C23H27NO5 (397.18891320000006)
A natural product found in Aconitum vilmorinianum and Delphinium denudatum.
methyl 2-[1-(4-fluorobenzyl)-1h-indazole-3-carboxamido]-3,3-dimethylbutanoate
15-acetyloxysongoramine|15-Acetylsongoramine
C24H31NO4 (397.22529660000004)
dihydroprecondylocarpine acetate
An organic cation which is an intermediate in the biosynthetic pathway leading to the synthesis of the monoterpenoid indole alkaloids, catharanthine and tabersonine.
Heliosupin
Heliosupine is an azabicycloalkane compound having angelyloxy and echimidinyloxymethyl substituents attached to the ring system. It is an azabicycloalkane, a diester and a 2-methylbut-2-enoic acid. It is functionally related to an angelic acid and an isocrotonic acid. Heliosupine is a natural product found in Cynoglossum australe, Paracaryum rugulosum, and other organisms with data available. See also: Comfrey Leaf (part of); Comfrey Root (part of). An azabicycloalkane compound having angelyloxy and echimidinyloxymethyl substituents attached to the ring system.
C19H27NO8_2-(4,5-Dihydroxy-7,7a-dimethyl-2-oxo-4,5,6,7,7a,7b-hexahydronaphtho[1,2-b]oxiren-1a(2H)-yl)-2-propen-1-yl 4-amino-2,3-dihydroxybutanoate
Ala Gly His Asn
Ala Gly Asn His
Ala His Gly Asn
Ala His Asn Gly
Ala Asn Gly His
Ala Asn His Gly
Ala Asn Pro Pro
Ala Pro Asn Pro
Ala Pro Pro Asn
Gly Ala His Asn
Gly Ala Asn His
Gly Gly His Lys
Gly Gly His Gln
Gly Gly Lys His
Gly Gly Gln His
Gly His Ala Asn
Gly His Gly Lys
Gly His Gly Gln
Gly His Lys Gly
Gly His Asn Ala
Gly His Gln Gly
Gly Lys Gly His
Gly Lys His Gly
Gly Lys Pro Pro
Gly Asn Ala His
Gly Asn His Ala
Gly Pro Lys Pro
Gly Pro Pro Lys
Gly Pro Pro Gln
Gly Pro Gln Pro
Gly Gln Gly His
Gly Gln His Gly
Gly Gln Pro Pro
His Ala Gly Asn
His Ala Asn Gly
His Gly Ala Asn
His Gly Gly Lys
His Gly Gly Gln
His Gly Lys Gly
His Gly Asn Ala
His Gly Gln Gly
His Lys Gly Gly
His Asn Ala Gly
His Asn Gly Ala
His Gln Gly Gly
Lys Gly Gly His
Lys Gly His Gly
Lys Gly Pro Pro
Lys His Gly Gly
Lys Pro Gly Pro
Lys Pro Pro Gly
Asn Ala Gly His
Asn Ala His Gly
Asn Ala Pro Pro
Asn Gly Ala His
Asn Gly His Ala
Asn His Ala Gly
Asn His Gly Ala
Asn Pro Ala Pro
Asn Pro Pro Ala
Pro Ala Asn Pro
Pro Ala Pro Asn
Pro Gly Lys Pro
Pro Gly Pro Lys
Pro Gly Pro Gln
Pro Gly Gln Pro
Pro Lys Gly Pro
Pro Lys Pro Gly
Pro Asn Ala Pro
Pro Asn Pro Ala
Pro Pro Ala Asn
Pro Pro Gly Lys
Pro Pro Gly Gln
Pro Pro Lys Gly
Pro Pro Asn Ala
Pro Pro Gln Gly
Pro Gln Gly Pro
Pro Gln Pro Gly
Gln Gly Gly His
Gln Gly His Gly
Gln Gly Pro Pro
Gln His Gly Gly
Gln Pro Gly Pro
Gln Pro Pro Gly
Dibutanoyllecithin
Dibutyroyl lecithin
PC(O-9:0/O-1:0)[U]
C18H40NO6P (397.2593110000001)
PC(9:0/0:0)
PC(9:0/0:0)[U]
PC(0:0/9:0)[U]
(±)14(15)-EET-SI
C21H35NO4S (397.2286670000001)
Drotaverin
C24H31NO4 (397.22529660000004)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AD - Papaverine and derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Bz-Arg-4-Abz-OH hydrochloride salt
C20H23N5O4 (397.17499580000003)
A-443654
A-443654 is a pan-Akt inhibitor and has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM)[1].
diperodon
C22H27N3O4 (397.20014620000006)
C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
1-[3-(9,9-dimethylfluoren-2-yl)phenyl]isoquinoline
[(1S)-1-(5-Fluoro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)propyl]carbamic acid 1,1-dimethylethyl ester
Chromonar hydrochloride
C20H28ClNO5 (397.1655908000001)
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
3-N-BOC-AMINO-1-[2-AMINO-1-(3-PHENOXY-PHENYL)-ETHYL]-PYRROLIDINE
C23H31N3O3 (397.23652960000004)
4-(9H-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxy]butanoic acid
C23H27NO5 (397.18891320000006)
CA-074 methyl ester
3-(2,2-diphenylethyl)-5-(2-piperidin-1-ylethyl)-1,2,4-oxadiazole,hydrochloride
C23H28ClN3O (397.19207880000005)
Diethylamino hydroxybenzoyl hexyl benzoate
C24H31NO4 (397.22529660000004)
4-[2,6-bis(2,4-dimethylphenyl)-1H-1,3,5-triazin-4-ylidene]-3-hydroxycyclohexa-2,5-dien-1-one
1-[(2-methylpropan-2-yl)oxycarbonyl]-4-(4-phenylmethoxyphenyl)pyrrolidine-3-carboxylic acid
C23H27NO5 (397.18891320000006)
4-(2-(BENZYL(METHYL)AMINO)ETHYL)-1,2-PHENYLENE BIS(2-METHYLPROPANOATE)
C24H31NO4 (397.22529660000004)
4-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid
C23H27NO5 (397.18891320000006)
FMOC-(3S,4S, 5S)-4-AMINO-3-HYDROXY-5-METHYL HEPTANOIC ACID
C23H27NO5 (397.18891320000006)
6,7-dimethoxy-1-(3,4,5-triethoxyphenyl)isoquinoline
C23H27NO5 (397.18891320000006)
2,6-bis((S)-4-benzyl-4,5-dihydrooxazol-2-yl)pyridine
N-([1,1-biphenyl]-4-yl)-[1,1:4,1-terphenyl]-4-amine
ETHYL 5-((7-ETHOXY-7-OXOHEPTYL)OXY)-4-METHOXY-2-NITROBENZOATE
Butanoic acid, 3-(1,1-dimethylethoxy)-4-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (3S)
C23H27NO5 (397.18891320000006)
Cc-223
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2. Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.
Fadraciclib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
3-[5-(1h-Imidazol-1-Yl)-7-Methyl-1h-Benzimidazol-2-Yl]-4-[(Pyridin-2-Ylmethyl)amino]pyridin-2(1h)-One
C22H19N7O (397.16510040000003)
Platensimycin B3
C23H27NO5 (397.18891320000006)
A polycyclic cage that is the decarboxy derivative of platensimycin. It is isolated from Streptomyces platensis.
2-[8-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1,3-dimethyl-2,6-dioxo-7-purinyl]acetic acid methyl ester
C20H23N5O4 (397.17499580000003)
symphytine N-oxide
N-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methylpyrazole-3-carboxamide
(2S)-4-(2,5-Difluorophenyl)-N-methyl-2-phenyl-N-piperidin-4-YL-2,5-dihydro-1H-pyrrole-1-carboxamide
C23H25F2N3O (397.19655839999996)
2-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-D]pyrimidin-5-YL)-ethyl]-benzoylamino}-3-methyl-butyric acid
C20H23N5O4 (397.17499580000003)
(Methylpyridazine piperidine butyloxyphenyl)ethylacetate
C23H31N3O3 (397.23652960000004)
Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate
C18H28FN5O4 (397.21252200000004)
Drotaverine
C24H31NO4 (397.22529660000004)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AD - Papaverine and derivatives C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Reduced ketanserin
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hydroxypropan-2-yl] dodecanoate
Tetradeca-9,11-dienedioylcarnitine
C21H35NO6 (397.24642500000004)
(6E,9E)-Tetradeca-6,9-dienedioylcarnitine
C21H35NO6 (397.24642500000004)
(2E,4Z)-Tetradeca-2,4-dienedioylcarnitine
C21H35NO6 (397.24642500000004)
(2S)-1-[(2S)-3-methyl-1-oxo-2-[[oxo-[(2S,3S)-3-[oxo(propylamino)methyl]-2-oxiranyl]methyl]amino]pentyl]-2-pyrrolidinecarboxylic acid methyl ester
2-(4-Ethoxyphenyl)-3,4-dimethyl-7-[2-(1-pyrrolidinyl)ethylthio]pyrazolo[3,4-d]pyridazine
C21H27N5OS (397.19362120000005)
2-[[4,6-Bis(1-piperidinyl)-1,3,5-triazin-2-yl]thio]-1-phenylethanone
C21H27N5OS (397.19362120000005)
1-Decyl-sn-glycero-3-phosphocholine
C18H40NO6P (397.2593110000001)
2-[5-(3,4-diethoxyphenyl)-2-tetrazolyl]-N-(3-methoxyphenyl)acetamide
C20H23N5O4 (397.17499580000003)
2-[4-(5-chloro-2-methylphenyl)-1-piperazinyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide
C23H28ClN3O (397.19207880000005)
3-[2-Oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-1,3-diazaspiro[4.6]undecane-2,4-dione
C23H31N3O3 (397.23652960000004)
4-cinnamyl-N-(3,5-dimethoxyphenyl)-1-piperazinecarbothioamide
C22H27N3O2S (397.18238820000005)
N-[2-(4-morpholinyl)ethyl]-4-(phenylmethyl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide
C22H27N3O2S (397.18238820000005)
4-(2-Fluorophenyl)-1-[[1-[(4-methoxyphenyl)methyl]-5-tetrazolyl]methyl]-4-piperidinol
C21H24FN5O2 (397.19139359999997)
5-amino-N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2-methoxyphenyl)-4-triazolecarboxamide
C20H23N5O4 (397.17499580000003)
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
1-[2-[[(3,4-Difluoroanilino)-oxomethyl]amino]-2-methyl-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester
C19H25F2N3O4 (397.18130340000005)
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
(3Z)-1-(4-benzoylpyridin-1-ium-1-yl)-3-(1,3,3-trimethylindol-2-ylidene)propan-2-one
C26H25N2O2+ (397.19159299999995)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]oxan-3-yl]pyridine-3-carboxamide
C22H27N3O4 (397.20014620000006)
2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-pyridinylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
(3aR,6aS)-4-methylsulfonyl-1-[(E)-4-piperidin-1-ylbut-2-enoyl]-6-propan-2-yl-3,3a,6,6a-tetrahydro-2H-pyrrolo[3,2-b]pyrrol-5-one
C19H31N3O4S (397.20351660000006)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]oxan-3-yl]pyridine-3-carboxamide
C22H27N3O4 (397.20014620000006)
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-pyridinylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid methyl ester
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-cyclohexyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
N-cyclohexyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
N-[[(2S,3R,4R)-4-(hydroxymethyl)-1-[1-oxo-2-(3-pyridinyl)ethyl]-3-phenyl-2-azetidinyl]methyl]-2-methoxy-N-methylacetamide
C22H27N3O4 (397.20014620000006)
2-(dimethylamino)-N-[[(2S,3R,4R)-4-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-2-azetidinyl]methyl]-N-propan-2-ylacetamide
C19H31N3O4S (397.20351660000006)
2-(dimethylamino)-N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-2-azetidinyl]methyl]-N-propan-2-ylacetamide
C19H31N3O4S (397.20351660000006)
N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methoxyethyl)-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methoxyethyl)-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
(1R,2aS,8bS)-N-(4-fluorophenyl)-1-(hydroxymethyl)-4-(1-oxobutyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide
(1S,2aR,8bR)-N-(4-fluorophenyl)-1-(hydroxymethyl)-4-(1-oxobutyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide
(2S,3S)-1-acetyl-3-[4-(1-cyclopentenyl)phenyl]-2-(hydroxymethyl)-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide
C23H31N3O3 (397.23652960000004)
(2R,3R)-6-[cyclobutyl(oxo)methyl]-N-cyclopentyl-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C23H31N3O3 (397.23652960000004)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3-oxanyl]-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-cyclohexyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
N-cyclohexyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
N-cyclohexyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
N-cyclohexyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
N-cyclohexyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
N-cyclohexyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide
C20H35N3O5 (397.25765800000005)
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-pyridinylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-pyridinylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide
C22H27N3O4 (397.20014620000006)
N-[[(2R,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-2-(3-pyridinyl)ethyl]-3-phenyl-2-azetidinyl]methyl]-2-methoxy-N-methylacetamide
C22H27N3O4 (397.20014620000006)
N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-[1-oxo-2-(3-pyridinyl)ethyl]-3-phenyl-2-azetidinyl]methyl]-2-methoxy-N-methylacetamide
C22H27N3O4 (397.20014620000006)
2-(dimethylamino)-N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-2-azetidinyl]methyl]-N-propan-2-ylacetamide
C19H31N3O4S (397.20351660000006)
2-(dimethylamino)-N-[[(2S,3R,4S)-4-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-2-azetidinyl]methyl]-N-propan-2-ylacetamide
C19H31N3O4S (397.20351660000006)
2-(dimethylamino)-N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-2-azetidinyl]methyl]-N-propan-2-ylacetamide
C19H31N3O4S (397.20351660000006)
2-(dimethylamino)-N-[[(2R,3S,4R)-4-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-2-azetidinyl]methyl]-N-propan-2-ylacetamide
C19H31N3O4S (397.20351660000006)
N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methoxyethyl)-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-(2-methoxyethyl)-3-pyridinecarboxamide
C22H27N3O4 (397.20014620000006)
[(2R,3S,4S)-3-[4-(1-cyclopentenyl)phenyl]-1-(4,5-dimethyl-2-thiazolyl)-4-(ethylaminomethyl)-2-azetidinyl]methanol
(1R,2aR,8bR)-N-(4-fluorophenyl)-1-(hydroxymethyl)-4-(1-oxobutyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide
(1S,2aS,8bS)-N-(4-fluorophenyl)-1-(hydroxymethyl)-4-(1-oxobutyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide
(2R,3R)-1-acetyl-3-[4-(1-cyclopentenyl)phenyl]-2-(hydroxymethyl)-N-propan-2-yl-1,6-diazaspiro[3.3]heptane-6-carboxamide
C23H31N3O3 (397.23652960000004)
1-[(1R)-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
C23H31N3O3 (397.23652960000004)
(6R,7R,8S)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C23H31N3O3 (397.23652960000004)
(6R,7R,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C23H31N3O3 (397.23652960000004)
(2S,3S)-6-[cyclobutyl(oxo)methyl]-N-cyclopentyl-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptane-1-carboxamide
C23H31N3O3 (397.23652960000004)
7,7-Dimethyl-10-(4-propan-2-ylphenyl)-6,8,10,10a-tetrahydroindeno[1,2-b]quinoline-9,11-dione
2-(3,4-dimethylphenyl)-N-[(E)-(1,5-dimethyl-1H-pyrazol-4-yl)methylidene]quinoline-4-carbohydrazide
(4S)-6-chloro-2-methyl-4-(4-methylphenyl)-3-(2-piperidin-1-ylethyl)quinazolin-4-ol
C23H28ClN3O (397.19207880000005)
(3-Decoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C18H40NO6P (397.2593110000001)
2-Aminoethyl (2-hydroxy-3-tridecoxypropyl) hydrogen phosphate
C18H40NO6P (397.2593110000001)
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] dodecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] butanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] propanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] acetate
N-[[(3,4-Dihydro-6-methoxy-2,5,7,8-tetramethyl-2H-1-benzopyran)-2-yl]acetyl]anthanilic acid
C23H27NO5 (397.18891320000006)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] octanoate
(2-Pentanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(3-Acetyloxy-2-hexanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] heptanoate
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] nonanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] hexanoate
2-[(2-Acetamido-3-hydroxydecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Butanoylamino)-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)nonoxy]phosphoryl]oxyethyl-trimethylazanium
Phytosphingosine 1-phosphate
C18H40NO6P (397.2593110000001)
A phosphosphingolipid that is phytosphingosine bearing a phospho group at position 1.
O-acetyl-15alpha-stemmadenine(1+)
An ammonium ion resulting from the protonation of the tertiary amino group of O-acetyl-15alpha-stemmadenine. The major species at pH 7.3.
IC-87114
C22H19N7O (397.16510040000003)
4-Tetradecanamidobenzylphosphonic acid
C21H36NO4P (397.2381826000001)
symphytine oxide
A pyrrolizine that is the N-oxido derivative of symphytine. Isolated from extracts of comfrey root.
N-Demethyl MK-6884
N-Demethyl MK-6884 (compound 34) is a potent M4 mAChR allosteric modulator. N-Demethyl MK-6884 can be used in the studies of alzheimer's disease and other diseases mediated by the M4 mAChR[1].
(1r,7ar)-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-4-hydroxy-3-methylbut-2-enoate
(1r,7ar)-7-({[(2s)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
(1s,12s,14s,15e)-15-ethylidene-13-(hydroxymethyl)-6-methoxy-13-(methoxycarbonyl)-17-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-17-ium
(3z,7z,9s,12r,14r)-12-hydroxy-14-[(2s)-2-hydroxy-2-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]ethyl]-4,9-dimethyl-1-oxacyclotetradeca-3,7-dien-2-one
C20H31NO5S (397.19228360000005)
(1r,7ar)-7-({[(2r)-2,3-dihydroxy-2-isopropylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-4-hydroxy-3-methylbut-2-enoate
(7r,7ar)-1-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-7-{[(2e)-2-methylbut-2-enoyl]oxy}-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate
(1r,7ar)-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2s,3s)-2,3-dimethyloxirane-2-carboxylate
(2s,4s,5r,7s)-2,5-diamino-4-hydroxy-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino}octanedioic acid
8,16-dimethoxy-12,13,13-trimethyl-16-(3-methylbut-2-en-1-yl)-4,14-dioxa-2-azatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1(9),2,5,7,11(15)-pentaen-10-one
C23H27NO5 (397.18891320000006)
(3s,6s)-5-hydroxy-6-[(2r)-3-hydroxy-2-methylpropyl]-1-methyl-3-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-3,6-dihydropyrazin-2-one
C23H31N3O3 (397.23652960000004)
12-hydroxy-14-[2-hydroxy-2-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)ethyl]-4,9-dimethyl-1-oxacyclotetradeca-3,7-dien-2-one
C20H31NO5S (397.19228360000005)
(1s,7ar)-7-({[(2r)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
5,6,14,15-tetramethoxy-1-methyl-17-oxa-9-azapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-2,4,6,12,14,16(20)-hexaene
C23H27NO5 (397.18891320000006)
(7r,7ar)-1-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-7-{[(2z)-2-methylbut-2-enoyl]oxy}-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate
(1r)-3-hydroxy-4,5-dimethoxy-12',12'-dimethyl-4',6'-dioxa-12'-azaspiro[isoindole-1,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-1',3'(7'),8'-trien-12'-ium
methyl (1r,14r,15r,16s,20s)-14-(hydroxymethyl)-16-methoxy-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
C22H27N3O4 (397.20014620000006)
(1r,7ar)-7-({[(2r)-2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 3-methylbut-2-enoate
(1r,7ar)-7-({[(2r)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
7-({[2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2-methylbut-2-enoate
n-(2,6-dihydroxyphenyl)-3-{5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl}propanimidic acid
C23H27NO5 (397.18891320000006)
methyl 14-(hydroxymethyl)-16-methoxy-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
C22H27N3O4 (397.20014620000006)
7-{[(2,3-dihydroxy-2-isopropylbutanoyl)oxy]methyl}-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 4-hydroxy-3-methylbut-2-enoate
(1r,7ar)-7-({[(2s)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate
(12s,16s)-8,16-dimethoxy-12,13,13-trimethyl-16-(3-methylbut-2-en-1-yl)-4,14-dioxa-2-azatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1(9),2,5,7,11(15)-pentaen-10-one
C23H27NO5 (397.18891320000006)
(2r,3s,4as,4br,5's,7r,8as)-2'-hydroxy-5'-[(1r)-1-hydroxyethyl]-4a,7-dimethyl-2-(prop-1-en-1-yl)-4b,5,6,7,8,8a-hexahydro-2h,5'h-spiro[phenanthrene-3,3'-pyrrole]-4,4'-dione
C24H31NO4 (397.22529660000004)
(3e,7e,9s,12s,14r)-12-hydroxy-14-[(2s)-2-hydroxy-2-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]ethyl]-4,9-dimethyl-1-oxacyclotetradeca-3,7-dien-2-one
C20H31NO5S (397.19228360000005)
n-{6-[(1,4-diamino-2,5,6-trihydroxyhexan-3-yl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl}propanimidic acid
(1r,7ar)-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-4-hydroxy-3-methylbut-2-enoate
(1r,7ar)-7-({[(2r)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate
(1s,3s,5r,8r,9s,11s,14r,17r,18s)-5,7-dimethyl-12-methylidene-10,15,16-trioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate
C23H27NO5 (397.18891320000006)
2,5-diamino-4-hydroxy-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino}octanedioic acid
(5r,8r)-8,16-dimethoxy-4,4,5-trimethyl-8-(3-methylbut-2-en-1-yl)-3,12-dioxa-10-azatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1(9),2(6),10,13,15-pentaen-7-one
C23H27NO5 (397.18891320000006)
7-{[(2,3-dihydroxy-2-isopropylbutanoyl)oxy]methyl}-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2,3-dimethyloxirane-2-carboxylate
(7r,7ar)-1-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-7-[(3-methylbut-2-enoyl)oxy]-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate
(1s,19s)-5,6,14,15-tetramethoxy-1-methyl-17-oxa-9-azapentacyclo[10.6.2.0²,⁷.0⁹,¹⁹.0¹⁶,²⁰]icosa-2,4,6,12,14,16(20)-hexaene
C23H27NO5 (397.18891320000006)
n-(2,6-dihydroxyphenyl)-3-[(1s,5s,6r,7s,9s,10s)-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1⁷,¹⁰.0¹,⁶]tridec-2-en-5-yl]propanimidic acid
C23H27NO5 (397.18891320000006)
(2r,3r,4as,4br,5'r,7r,8as)-2'-hydroxy-5'-[(1r)-1-hydroxyethyl]-4a,7-dimethyl-2-(prop-1-en-1-yl)-4b,5,6,7,8,8a-hexahydro-2h,5'h-spiro[phenanthrene-3,3'-pyrrole]-4,4'-dione
C24H31NO4 (397.22529660000004)
8,16-dimethoxy-4,4,5-trimethyl-8-(3-methylbut-2-en-1-yl)-3,12-dioxa-10-azatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1(9),2(6),10,13,15-pentaen-7-one
C23H27NO5 (397.18891320000006)
n-[(3s,6r)-6-{[(2s,3s,4r,5s)-1,4-diamino-2,5,6-trihydroxyhexan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]propanimidic acid
(1r,7ar)-7-({[(2r)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 3-methylbut-2-enoate
2,5-diamino-4-hydroxy-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino}octanedioic acid
(3s,5r,8r,9s,11s,14r,17r,18s)-5,7-dimethyl-12-methylidene-10,15,16-trioxo-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl acetate
C23H27NO5 (397.18891320000006)
13-amino-16-(hydroxymethyl)-20-methyl-11,14-dioxo-5-oxa-8,17,20-triazahexacyclo[15.3.1.0³,¹⁹.0⁴,⁸.0⁹,¹⁸.0¹⁰,¹⁵]henicosa-10(15),12-diene-21-carbonitrile
C20H23N5O4 (397.17499580000003)